Full Press Release Details
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease.
CRSP
CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
Key Takeaway: CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease
Price reaction · baseline $68.65 (2023-12-01 close) · clean, no other CRSP news in the window
day 0 close · peak
+4.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+60%
120-day peak, hindsight
Typical move
2.4%
average across 2 past catalysts
Cash runway
~84 mo
Minimal dilution risk
Lead asset
CTX340
Phase 1 · Hypertension